Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JMAC Maxpro Capital Acquisition	$6.47 +6.6%	$6.11	$7.50 ▼ $19.22	$86.94M	0.01	74,040 shs	2,426 shs
OVID Ovid Therapeutics	$0.30 +4.1%	$0.30	$0.24 ▼ $1.47	$19.92M	0.08	439,501 shs	777,334 shs
SRZN Surrozen	$9.22 -3.4%	$8.93	$5.90 ▼ $18.17	$81.14M	0.57	21,145 shs	15,293 shs
ZURA Zura Bio	$1.14 -5.0%	$1.21	$0.97 ▼ $5.07	$82.05M	-0.12	437,025 shs	297,619 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JMAC Maxpro Capital Acquisition	+6.61%	-0.39%	+32.40%	-18.66%	+3,121.09%
OVID Ovid Therapeutics	+4.06%	-5.82%	-0.20%	-37.00%	-61.70%
SRZN Surrozen	-3.35%	+3.13%	+29.86%	-18.45%	-16.18%
ZURA Zura Bio	-5.00%	-10.94%	+2.70%	-19.72%	-69.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	4.3876 of 5 stars	3.5	3.0	0.0	4.6	2.7	2.5	0.6
SRZN Surrozen	3.8277 of 5 stars	3.5	3.0	0.0	0.0	3.8	5.0	0.6
ZURA Zura Bio	2.4873 of 5 stars	3.6	1.0	0.0	0.0	2.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JMAC Maxpro Capital Acquisition	0.00	N/A	N/A	N/A
OVID Ovid Therapeutics	3.20	Buy	$3.13	933.40% Upside
SRZN Surrozen	3.00	Buy	$38.50	317.57% Upside
ZURA Zura Bio	3.13	Buy	$14.33	1,157.31% Upside

Current Analyst Ratings Breakdown

Latest OVID, ZURA, SRZN, and JMAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	OVID Ovid Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$2.00 ➝ $1.50
5/12/2025	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
5/9/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$19.00 ➝ $17.00
4/24/2025	OVID Ovid Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
4/2/2025	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
3/26/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$20.00 ➝ $19.00
3/26/2025	ZURA Zura Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/26/2025	ZURA Zura Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
3/24/2025	OVID Ovid Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	$570K	37.73	N/A	N/A	$0.96 per share	0.32
SRZN Surrozen	$10.65M	7.41	N/A	N/A	($6.55) per share	-1.41
ZURA Zura Bio	N/A	N/A	N/A	N/A	$2.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JMAC Maxpro Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	-$26.43M	-$0.35	N/A	N/A	N/A	-4,562.23%	-34.17%	-25.34%	8/12/2025 (Estimated)
SRZN Surrozen	-$63.56M	-$24.96	N/A	N/A	N/A	N/A	-842.90%	-71.32%	8/11/2025 (Estimated)
ZURA Zura Bio	-$45.39M	-$0.70	N/A	N/A	N/A	N/A	-42.84%	-35.22%	8/12/2025 (Estimated)

Latest OVID, ZURA, SRZN, and JMAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	OVID Ovid Therapeutics	-$0.14	-$0.14	N/A	-$0.14	$0.03 million	$0.13 million
5/9/2025	Q1 2025	SRZN Surrozen	-$1.09	-$3.13	-$2.04	-$7.43	N/A	$0.98 million
5/8/2025	Q1 2025	ZURA Zura Bio	-$0.17	-$0.19	-$0.02	-$0.19	N/A	N/A
3/31/2025	Q4 2024	SRZN Surrozen	-$2.54	-$9.10	-$6.56	-$9.10	N/A	$0.66 million
3/25/2025	Q4 2024	ZURA Zura Bio	-$0.17	-$0.08	+$0.09	-$0.08	N/A	$0.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A
OVID Ovid Therapeutics	0.18	5.66	5.66
SRZN Surrozen	N/A	7.40	7.40
ZURA Zura Bio	N/A	10.36	10.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JMAC Maxpro Capital Acquisition	73.18%
OVID Ovid Therapeutics	72.24%
SRZN Surrozen	66.57%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
JMAC Maxpro Capital Acquisition	19.27%
OVID Ovid Therapeutics	13.10%
SRZN Surrozen	43.50%
ZURA Zura Bio	22.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JMAC Maxpro Capital Acquisition	2,021	13.43 million	10.84 million	Not Optionable
OVID Ovid Therapeutics	60	71.11 million	61.80 million	Optionable
SRZN Surrozen	80	8.56 million	4.84 million	Not Optionable
ZURA Zura Bio	3	68.38 million	53.26 million	Optionable

OVID, ZURA, SRZN, and JMAC Headlines

Recent News About These Companies

Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of "Buy" by Analysts

June 18 at 3:38 AM | marketbeat.com

Cantor Fitzgerald Weighs in on Zura Bio FY2026 Earnings

June 11, 2025 | marketbeat.com

Millennium Management LLC Has $1.75 Million Position in Zura Bio Limited (NASDAQ:ZURA)

June 3, 2025 | marketbeat.com

Zura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of "Buy" by Brokerages

May 26, 2025 | marketbeat.com

Zura Bio shareholders approve board nominees and auditor

May 24, 2025 | investing.com

HC Wainwright Issues Positive Estimate for Zura Bio Earnings

May 23, 2025 | marketbeat.com

Q1 Earnings Estimate for Zura Bio Issued By HC Wainwright

May 22, 2025 | marketbeat.com

Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa

May 21, 2025 | msn.com

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 20, 2025 | businesswire.com

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 9, 2025 | standard-journal.com

After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain

April 24, 2025 | finance.yahoo.com

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Zura Bio (ZURA) Gets a Buy from Guggenheim

March 31, 2025 | markets.businessinsider.com

Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock

March 26, 2025 | finance.yahoo.com

Zura Bio Limited: 2024 Financial Results and Strategic Progress

March 26, 2025 | tipranks.com

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

March 25, 2025 | businesswire.com

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

February 24, 2025 | businesswire.com

ZURA stock touches 52-week low at $1.44 amid market shifts

February 11, 2025 | msn.com

Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)

January 24, 2025 | zacks.com

We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth

January 22, 2025 | finance.yahoo.com

Zura Bio Highlights Strategic Goals and Clinical Advances

January 13, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Government Mandate Sends eVTOL Stocks Flying
By Jeffrey Neal Johnson | June 10, 2025
View Government Mandate Sends eVTOL Stocks Flying
GitLab: Buy It Low While You Still Can—Higher Prices Are Coming
By Thomas Hughes | June 11, 2025
View GitLab: Buy It Low While You Still Can—Higher Prices Are Coming
These ETFs Provide Easy Exposure to Growing International Markets
By Nathan Reiff | May 24, 2025
View These ETFs Provide Easy Exposure to Growing International Markets
3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
By Nathan Reiff | June 9, 2025
View 3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge

OVID, ZURA, SRZN, and JMAC Company Descriptions

Maxpro Capital Acquisition NASDAQ:JMAC

$6.47 +0.40 (+6.61%)

As of 06/16/2025

Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.

Ovid Therapeutics NASDAQ:OVID

$0.30 +0.01 (+4.06%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$0.31 +0.00 (+1.19%)

As of 04:42 AM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Surrozen NASDAQ:SRZN

$9.22 -0.32 (-3.35%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$9.20 -0.02 (-0.22%)

As of 06/17/2025 04:04 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

Zura Bio NASDAQ:ZURA

$1.14 -0.06 (-5.00%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$1.18 +0.04 (+3.51%)

As of 06/17/2025 06:33 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time